Welcome to our dedicated page for Editas Medicine SEC filings (Ticker: EDIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Editas Medicine, Inc. filings document regulatory disclosures for a clinical-stage genome editing company developing CRISPR-based in vivo medicines. Recent 8-K filings report operating results and financial condition, business highlights, EDIT-401 development disclosures, scientific data furnished under Regulation FD, and other events tied to CRISPR intellectual property matters.
The filing record also includes proxy materials covering board governance, executive compensation and equity awards, along with material-event reporting on a change in independent registered public accounting firm. These disclosures frame the company’s pipeline, capital resources, governance practices, risk areas and public-company reporting obligations.
Editas Medicine reported first quarter 2026 results and highlighted progress on its lead in vivo gene-editing program, EDIT-401, for hyperlipidemia and HeFH. Preclinical data showed more than 90% mean LDL-C reduction, and the company plans to start a first-in-human trial in 2026 with early proof-of-concept data expected by year-end and dose-finding topline data in 2027.
Cash and cash equivalents were $123.6 million as of March 31, 2026, which the company expects will fund operations into the third quarter of 2027. Net loss narrowed to $25.0 million, or $0.26 per share, compared with a net loss of $76.1 million, or $0.92 per share, a year earlier, driven by lower R&D and G&A expenses and the absence of prior-year restructuring and impairment charges.
Collaboration and other research and development revenues were $2.8 million, down from $4.7 million in the prior-year quarter, primarily because 2025 included remaining deferred revenue recognized when a collaboration ended. The U.S. Patent and Trademark Office also reaffirmed a prior Patent Trial and Appeal Board decision favoring the Broad Institute in a CRISPR/Cas9 interference involving patents exclusively licensed to Editas for use in human cells.
Editas Medicine filed its Annual Report on Form 10-K reporting continued focus on in vivo CRISPR gene editing and the nomination of its lead candidate, EDIT-401, an in vivo LDLR upregulation program that produced ~90% mean LDL-C reductions in non-human primates. The company plans an IND or foreign equivalent for EDIT-401 by mid-2026, expects early human proof-of-concept by the end of 2026, and topline dose-finding results in 2027. The report discloses 97,871,999 shares outstanding as of February 27, 2026 and an aggregate market value held by non-affiliates of approximately $191,377,146 as of June 30, 2025. The filing restates strategic priorities: advance EDIT-401, continue HSC and extrahepatic LNP work, and monetize IP via collaborations and licenses.
Editas Medicine has issued its definitive proxy statement for the 2026 virtual annual meeting on June 17, 2026, where stockholders will elect two Class I directors, cast an advisory vote on executive pay, and ratify PricewaterhouseCoopers as auditor.
The company highlights its strategic shift to a fully in vivo gene editing preclinical model, including lead candidate EDIT-401 for LDL‑cholesterol with preclinical LDL‑C reductions exceeding 90% in non‑human primates. Management reports extending its cash runway into the third quarter of 2027, supported in part by an at‑the‑market offering program.
Governance and pay practices emphasize board independence, a separate chair and CEO, annual say‑on‑pay, anti‑hedging and clawback policies, and substantial performance-based pay, with approximately 73% of CEO target compensation and 54% of other named executive officer target compensation designated as performance-based. The board determined 2025 corporate objectives were achieved at 91% of target for bonus purposes and is recommending stockholders vote in favor of all three proposals.
Editas Medicine, Inc. has replaced its long-time auditor, dismissing Ernst & Young LLP and appointing PricewaterhouseCoopers LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2026.
The Audit Committee made the change after soliciting proposals and conducting a formal review. Ernst & Young’s audit reports for 2024 and 2025 contained no adverse opinions or qualifications, and the company reports no disagreements or reportable events with Ernst & Young through April 1, 2026.
Editas Medicine announced that the U.S. Patent and Trademark Office has reaffirmed the Patent Trial and Appeal Board’s prior decision favoring the Broad Institute in a key CRISPR/Cas9 patent interference covering gene editing in human cells. This is the PTAB’s third favorable decision confirming Broad as first to invent CRISPR/Cas9 use in eukaryotic cells.
The CRISPR/Cas9 patents at issue are exclusively licensed to Editas for developing and commercializing CRISPR/Cas9-based medicines, underpinning its gene editing pipeline. Other in-licensed Broad, Harvard, MIT and collaborator patents, including CRISPR/Cas12a rights, are not involved in this interference and remain unaffected.
Management highlighted this outcome as reinforcing confidence in the company’s intellectual property as it advances in vivo gene editing programs, including EDIT-401, an experimental one-time therapy that has achieved greater than 90 percent mean LDL cholesterol reduction in non-human primates. CVC parties retain the right to appeal the decision to the Federal Circuit.
The Vanguard Group filed an amendment (Schedule 13G/A) reporting that it beneficially owns 0 shares of Editas Medicine common stock, representing 0% of the class. The filing explains an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries to report holdings separately.
Editas Medicine, Inc. reported that CEO O'Neill Gilmore Neil received a grant of stock options covering 1,015,200 shares of common stock at an exercise price of $2.54 per share. The options were granted as compensation and have no purchase price at grant.
The award is scheduled to vest over four years in equal monthly installments, beginning on April 12, 2026 and continuing through March 12, 2030, aligning the CEO’s long-term incentives with company performance over that period.
Editas Medicine, Inc. reported that its SVP and Chief Financial Officer, Amy Parison, received a grant of stock options covering 292,856 shares of common stock. The options have an exercise price of $2.54 per share and were granted as a compensation award, not an open-market purchase.
According to the disclosure, the options were granted on March 12, 2026 and are scheduled to vest over four years in equal monthly installments from April 12, 2026 through March 12, 2030. Following this award, she holds 292,856 option-based rights to acquire Editas Medicine common shares directly.
Editas Medicine, Inc. reported that EVP and Chief Scientific Officer Linda Burkly received a grant of stock options covering 292,856 shares of common stock. The options have an exercise price of $2.54 per share and expire on March 11, 2036.
The award was granted on March 12, 2026 and is scheduled to vest over four years in equal monthly installments from April 12, 2026 through March 12, 2030. Following this grant, Burkly holds 292,856 stock options from this award.
Editas Medicine, Inc. provides an overview of its business and strategy as a CRISPR-based gene editing company focused on in vivo genomic medicines. The company’s lead development candidate, EDIT-401, is designed as a one-time therapy to upregulate the LDL receptor and significantly lower LDL cholesterol in patients with hyperlipidemia, including heterozygous familial hypercholesterolemia.
Editas is building a “plug ’n play” lipid nanoparticle platform to deliver CRISPR medicines to the liver, hematopoietic stem cells, and other tissues, and is shifting resources from its former ex vivo sickle cell program to in vivo approaches. The company also outlines multiple collaborations and licensing deals, including a non‑exclusive Cas9 license to Vertex for sickle cell disease and beta thalassemia and a royalty‑monetization agreement with DRI Healthcare Trust, alongside a broad patent estate licensed from Broad, Harvard, and others covering Cas9 and Cas12a technologies.